Page 35
A n n u a l S u mm i t o n
Hepatology and Pancreatic
Diseases
November 12-13 , 2018
Par i s , France
Journal of Clinical Gastroenterology and Hepatology
ISSN: 2575-7733
Hepatology and Pancreatic Diseases 2018
N
on-alcoholic fatty liver disease (NAFLD) is one of the most common forms of chronic liver disease which may progress to non-
alcoholic steatohepatitis (NASH). Currently there are no therapeutic strategies for such disease. Only lifestyle modification
through diet and exercise were proven to afford some benefit in patients with NAFLD. No pharmacologic agents have so far been
approved for the treatment of NAFLD or NASH. Therefore, most clinical efforts have been directed at treating the components
of metabolic syndrome, namely obesity, diabetes, hypertension and dyslipidemias. Other interventions are directed at specific
pathways potentially involved in the pathogenesis of NAFLD, such as insulin resistance, oxidative stress, pro-inflammatory
cytokines, apoptosis, bacterial overgrowth, and angiotensin pathway. This lecture aims to show the potential of Tocotrienols as a
promising therapeutic option for NAFLD. This is a Systematic Review of the effects of Tocotrienols on Non-Alcoholic Fatty Liver
Disease. (NAFLD). Tocotrienols may yet prove to be an effective treatment for Non-Alcoholic Fatty Liver Disease
genemapmd@yahoo.comThe Efficacy of Tocotrienols in the Treatment of
Non-alcoholic Steatohepatitis: A Systematic Review
Higinio T. Mappala
Jose Reyes Mem. Medical Center, Philippines
J Clin Gastroenterol Hepatol 2018, Volume:2
DOI: 10.21767/2575-7733-C3-009




